StockData
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc. (RXRX) stock

RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)

Close on Nov 16, 2026Market cap $1.56BP/E –Yield –

Recursion Pharmaceuticals enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Recursion Pharmaceuticals's enterprise value was $1.39B on Nov 11, 2026, against $1.63B a year earlier. Over the last 5 years it ranged from $352.60M to $2.75B, with a median of $1.38B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$1.39B+1.5%
2025Dec 31, 2025$1.37B-10.6%
2024Dec 31, 2024$1.53B-12.1%
2023Dec 29, 2023$1.74B+97.9%
2022Dec 30, 2022$877.77M-61.8%
2021Dec 31, 2021$2.30B–

More Recursion Pharmaceuticals figures

See a number that looks wrong?